menu
    • menu
    [{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Trientine Tetrahydrochloride","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orphalan \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orphalan \/ Not Applicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Trientine Tetrahydrochloride","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orphalan \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orphalan \/ Not Applicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Trientine Tetrahydrochloride","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orphalan \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orphalan \/ Not Applicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Trientine Tetrahydrochloride","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orphalan \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orphalan \/ Not Applicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Trientine Tetrahydrochloride","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orphalan \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orphalan \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Orphalan

    Menu

    Orphalan

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orphalan

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Orphalan

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trientine Tetrahydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orphalan Announces China Approval for Trientine Tetrahydrochloride Product

                            Details : Cuprior (trientine tetrahydrochloride) is a copper chelator that removes absorbed copper from the body by forming a stable complex eliminated through urine, for treating Wilson disease.

                            Brand Name : Cuprior

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 18, 2024

                            Lead Product(s) : Trientine Tetrahydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orphalan

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Orphalan

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trientine Tetrahydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orphalan Announces US Commercial Launch of Cuvrior™ for the Treatment of Wilson Disease

                            Details : Cuvrior (trientine hydrochloride) is a copper chelator that forms a complex with absorbed copper and then gets eliminated through urinary excretion. It is available in US for the treatment of stable Wilson disease who are de-coppered and tolerant to peni...

                            Brand Name : Cuvrior

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 20, 2023

                            Lead Product(s) : Trientine Tetrahydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Orphalan

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Orphalan

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trientine Tetrahydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orphalan Announces Publication of Results from the CHELATE Trial in The Lancet Gastroenterology & Hepatology

                            Details : Using this NCC measurement Cuvrior (trientine tetrahydrochloride) was determined to be non-inferior to penicillamine at primary endpoint of study (24 weeks), with same observation at end of extension phase of study in patients receiving maintenance penic...

                            Brand Name : Cuvrior

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 30, 2022

                            Lead Product(s) : Trientine Tetrahydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Orphalan

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Orphalan

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trientine Tetrahydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orphalan Announces Data From Secondary Analyses of the CHELATE Trial for Maintenance Patients With Wilson’s ...

                            Details : Cuvrior™ (trientine tetrahydrochloride) is an oral trientine formulation. In the U.S., trientine tetrahydrochloride has been granted Orphan Drug Designation for the treatment of Wilson’s disease.

                            Brand Name : Cuvrior

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2022

                            Lead Product(s) : Trientine Tetrahydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Orphalan

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Orphalan

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trientine Tetrahydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orphalan Announces FD Approval of Cuvrior™ for the Treatment of Adult Patients With Stable Wilson’s Diseas...

                            Details : Orphalan recently completed a global phase III trial, CHELATE, which met its primary efficacy endpoint by demonstrating that Cuvrior, a new salt of trientine (trientine tetrahydrochloride) was non-inferior to penicillamine as measured by non-ceruloplasmi...

                            Brand Name : Cuvrior

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 02, 2022

                            Lead Product(s) : Trientine Tetrahydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth